Intellipharmaceutics International Inc. (the “Company”) is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs.
Company profile
Ticker
IPCIF, IPCIF
Exchange
Website
CEO
Isa Odidi
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
IntelliPharmaCeutics International Inc.
SEC CIK
IPCIF stock data
Latest filings (excl ownership)
6-K
Intellipharmaceutics International Inc. Announces Transfer of Listing to NEX and New Stock Option Plan
13 Mar 24
6-K
Intellipharmaceutics Announces Cease Trade Order
7 Mar 24
6-K
Intellipharmaceutics Announces its Expected Delay in Filing Annual Audited Financial Statements and Annual Information Form
26 Feb 24
UPLOAD
Letter from SEC
14 Feb 24
6-K
Intellipharmaceutics International Inc. Announces Stock Option Grant
9 Feb 24
20-F/A
2023 FY
Annual report (foreign) (amended)
6 Feb 24
6-K
Intellipharmaceutics International Inc. Receives Conditional Approval to List on the TSX Venture Exchange
11 Jan 24
6-K
Current report (foreign)
16 Oct 23
6-K
Annual Meeting of Shareholders
6 Oct 23
6-K
Intellipharmaceutics Reports Director Election Results
6 Oct 23
Latest ownership filings
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 23
SC 13G/A
ARMISTICE CAPITAL, LLC
15 Feb 22
SC 13G
ARMISTICE CAPITAL, LLC
16 Feb 21
SC 13G/A
Intellipharmaceutics International Inc.
11 Feb 20
SC 13G/A
Intellipharmaceutics International Inc.
21 Jan 20
SC 13D/A
Intellipharmaceutics International Inc.
18 Nov 19
SC 13G/A
Intellipharmaceutics International Inc.
14 Feb 19
SC 13G/A
Intellipharmaceutics International Inc.
14 Feb 19
SC 13G/A
Intellipharmaceutics International Inc.
1 Feb 19
Financial summary
Quarter (USD) | Nov 22 | Dec 20 | Nov 20 | Nov 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Nov 22 | Dec 20 | Nov 20 | Nov 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 83.72 k | 83.72 k | 83.72 k | |||
Cash burn (monthly) | 536.65 k | 228.28 k | 72.02 k | |||
Cash used (since last report) | 8.58 mm | 3.65 mm | 1.15 mm | |||
Cash remaining | -8.49 mm | -3.56 mm | -1.07 mm | |||
Runway (months of cash) | -15.8 | -15.6 | -14.8 |
Institutional ownership, Q1 2021
7.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 2.63 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Armistice Capital | 2.63 mm | $0.00 |